Nuclear Medicine Market Size & Growth Forecast 2027–2036, By Segments (Product, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Nuclear Medicine Market size was assessed at USD 24.1 billion in 2026 and is poised to grow at a 6.46% CAGR between 2027 and 2036, exceeding USD 45.07 billion by 2036. The industry revenue for 2027 is calculated at USD 25.41 billion.
Base Year Value (2026)
USD 24.1 billion
CAGR (2027-2036)
6.46%
Forecast Year Value (2036)
USD 45.07 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036
Nuclear Medicine Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America leads with a 45.44% share, supported by advanced healthcare infrastructure, widespread diagnostic and therapeutic procedures, and strong radioisotope supply and clinical networks across hospitals and specialty centers.
- Asia Pacific growth at 13.1% CAGR is driven by rising healthcare investment, expanded access to diagnostic imaging, and increasing adoption of radiopharmaceutical therapies across developing hospital systems.
-
Segment Momentum:
- Diagnostics held a 73.49% share in 2026 due to their widespread use in disease detection, staging, and treatment monitoring, making them a routine component of clinical and imaging workflows.
- Hospitals held a 57.75% market share in 2026 and are growing fastest because they combine imaging infrastructure, radiopharmaceutical management, multidisciplinary care, and patient monitoring within a single setting.
-
Market Expansion Drivers:
- Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies.
- Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates.
- Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments.
-
Leading Market Participants:
Key companies in the nuclear medicine market include GE HealthCare Technologies Inc. (United States), Cardinal Health, Inc. (United States), Lantheus Holdings, Inc. (United States), Bracco Imaging S.p.A. (Italy), Mallinckrodt plc (Ireland), Eckert & Ziegler SE (Germany), Nordion Inc. (Canada), Curium Pharma (France), Jubilant Pharmova Limited (India), Eczacıbaşı-Monrol Nuclear Products Co. (Turkey).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2026 Market Size: USD 24.1 billion
- 2027 Estimated Market Size: USD 25.41 billion.
- Projected Market Size: USD 45.07 billion by 2036
- Growth Forecasts: 6.46% CAGR (2027-2036)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diagnostics (Product) | Hospitals (End Use) | Urology (Application)
- Emerging Opportunity Segment: Therapeutics (Product) | Hospitals (End Use) | Urology (Application)
Market Growth Drivers and Industry Trends
Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies
The increasing prevalence of cancer is strengthening demand for diagnostic and therapeutic approaches that can identify disease sites and deliver treatment with greater precision. The nuclear medicine market will benefit from this trend as radiopharmaceuticals enable targeted imaging and therapies for various cancer-related applications. Greater emphasis on earlier detection and more precise treatment selection is increasing the role of nuclear medicine within oncology care pathways.
Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates
The integration of diagnostic imaging and targeted treatment through theranostics is expanding the clinical applications of nuclear medicine in precision oncology. Advances in this approach will propel the nuclear medicine market as clinicians can use molecular characteristics identified through imaging to guide the selection of targeted radiopharmaceutical therapies. Increasing focus on individualized treatment strategies is also encouraging broader clinical utilization of nuclear technologies across cancer diagnosis, patient selection, and treatment monitoring.
Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments
Supportive reimbursement frameworks and government funding can improve the affordability and availability of radiopharmaceutical-based procedures across healthcare systems. Favorable policies will drive nuclear medicine market demand by reducing financial barriers for healthcare providers and patients seeking specialized diagnostic and therapeutic services. Public investment can also support the development of nuclear medicine infrastructure, treatment facilities, and broader access to radiopharmaceutical technologies.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer burden increasing demand for targeted radiopharmaceutical diagnostics and therapies | 2.40% | High | North America, Europe | High | Near Term |
| Expansion of theranostics and precision oncology improving nuclear medicine clinical adoption rates | 2.00% | High | North America, Asia Pacific | High | Mid Term |
| Favorable reimbursement policies and government funding expanding access to radiopharmaceutical treatments | 1.80% | High | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
45.44% Market Share in 2026
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)
The nuclear medicine market was led by North America, which accounted for a 45.44% share in 2026, supported by advanced healthcare infrastructure, broad availability of specialized diagnostic and therapeutic services, and strong adoption of sophisticated medical technologies. Established nuclear medicine capabilities and continued investment in precision diagnostics and targeted therapies are strengthening regional demand. The region also benefits from growing clinical emphasis on early disease detection and personalized treatment approaches. Asia Pacific represents the fastest-growing regional market, driven by expanding healthcare infrastructure, improving access to advanced diagnostic technologies, and increasing awareness of nuclear medicine applications. Greater investment in specialized medical facilities and the adoption of modern imaging and therapeutic technologies are supporting broader regional utilization.
Key Country Insights
The U.S. nuclear medicine market benefits from ongoing expansion of radiopharmaceutical development and advanced diagnostic imaging services. Healthcare providers continue investing in production capabilities and precision medicine applications that broaden clinical adoption.
Japan continues advancing nuclear medicine by supporting innovation in radiopharmaceutical research and specialized diagnostic procedures. Japanese healthcare providers increasingly integrate targeted imaging solutions into routine clinical practice for complex disease management.
South Korea expands nuclear medicine capabilities through investments in modern imaging infrastructure and domestic radiopharmaceutical development. Clinical centers increasingly adopt advanced diagnostic and therapeutic procedures to enhance precision healthcare services.
Germany strengthens nuclear medicine through close integration of diagnostic imaging, radiopharmaceutical production, and clinical research. Healthcare institutions prioritize advanced imaging technologies that improve workflow efficiency and personalized patient management.
France supports nuclear medicine through coordinated research initiatives and expanding clinical use of targeted radiopharmaceuticals. French healthcare organizations emphasize multidisciplinary collaboration to improve diagnostic accuracy and treatment planning across specialized care settings.
Italy strengthens its nuclear medicine market by modernizing hospital imaging facilities and improving access to advanced radiopharmaceutical services. Italian healthcare providers continue enhancing clinical capabilities through technology upgrades and specialized medical expertise.
Segment Leadership and Growth Trends
Product Segment Analysis: Diagnostics (Largest Segment) vs Therapeutics (Fastest-Growing Segment)
Diagnostics held the dominant position in the nuclear medicine market, accounting for a 73.49% share in 2026. The segment benefits from the established use of nuclear imaging in detecting, characterizing, and monitoring a broad range of diseases, particularly cancer and cardiovascular conditions. Nuclear diagnostic procedures provide functional information that complements conventional anatomical imaging, supporting more precise disease assessment and treatment planning. Increasing emphasis on earlier diagnosis, personalized clinical decision-making, and advanced imaging capabilities continues to sustain demand for nuclear medicine diagnostics.
Therapeutics is gaining momentum as nuclear medicine increasingly expands beyond disease detection toward targeted treatment. Radiopharmaceutical therapies can deliver radiation directly to specific disease sites, offering a more selective approach to managing certain cancers and other conditions. Growing clinical interest in targeted radionuclide treatment, advances in radiopharmaceutical development, and increasing emphasis on personalized care are supporting greater adoption of therapeutic nuclear medicine and strengthening its growth potential.
End Use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
Hospitals led the nuclear medicine market with a 57.75% share in 2026 and also represented the fastest-growing end-use segment. Their leading position reflects the broad availability of specialized imaging, radiopharmaceutical administration, diagnostic services, and multidisciplinary clinical expertise within hospital settings. Nuclear medicine is increasingly integrated into oncology, cardiology, and other specialized care pathways, allowing hospitals to use diagnostic and therapeutic procedures across complex patient needs. Expansion of advanced clinical capabilities and the growing role of precision medicine are further supporting nuclear medicine adoption within hospitals.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Product | Diagnostics, Therapeutics | Diagnostics | Therapeutics |
| End Use | Hospitals, Diagnostic Centers, Others | Hospitals | Hospitals |
| Application | Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor, Pulmonary Scans, Urology, Other | Urology | Urology |
Read our Research ApproachCompetitive Landscape and Market Positioning
Key companies in the nuclear medicine market:
1. GE HealthCare Technologies Inc. (United States)
2. Cardinal Health Inc. (United States)
3. Lantheus Holdings Inc. (United States)
4. Bracco Imaging S.p.A. (Italy)
5. Mallinckrodt plc (Ireland)
6. Eckert & Ziegler SE (Germany)
7. Nordion Inc. (Canada)
8. Curium Pharma (France)
9. Jubilant Pharmova Limited (India)
10. Eczacıbaşı-Monrol Nuclear Products Co. (Turkey)
The nuclear medicine market is expanding through advancements in radiopharmaceutical development and precision imaging technologies. Healthcare organizations are increasing focus on targeted diagnostics and therapeutic procedures that improve disease detection and treatment effectiveness. Ongoing investments in isotope production capabilities and specialized imaging systems are further supporting market evolution.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Bristol Myers Squibb | Dec-23 | Bristol Myers Squibb entered into a definitive agreement to acquire RayzeBio for $4.1 billion to expand its oncology portfolio. The acquisition integrates RayzeBio's pipeline of actinium-225-based radiopharmaceutical therapeutics currently in clinical trials, alongside related lutetium-177 programs, strengthening the company's long-term competitive position in targeted theranostics. |
| SHINE Technologies | Mar-26 | SHINE Technologies secured $240 million in a funding round led by NantWorks to accelerate the development of its nuclear medicine division. The capital will scale manufacturing infrastructure and expand production capacity for critical medical isotopes, specifically addressing supply chain vulnerabilities for SPECT imaging agents. |
| Lantheus Holdings, Inc. | Jan-24 | Lantheus Holdings solidified its oncology pipeline by executing strategic agreements with Perspective Therapeutics, including an upfront $28 million cash payment. The deal secures an exclusive option to license a lead-212-labeled alpha-radiopharmaceutical therapy for neuroendocrine tumors and establishes co-development rights for early-stage prostate cancer treatments. |
| Sanofi | Oct-24 | Sanofi and Orano Med formed a strategic agreement to co-invest in a new entity operating under the Orano Med brand. The joint venture focuses on the discovery, design, and clinical commercialization of next-generation radioligand therapies utilizing the alpha-emitting isotope lead-212 to treat rare cancers. |
| Catalyst MedTech | Apr-26 | Catalyst MedTech completed the acquisition of X3D to scale its original equipment manufacturer platform and enhance its footprint in nuclear medicine imaging. The transaction integrates specialized radiological imaging technologies into Catalyst's portfolio, optimizing diagnostic workflows and clinical software compatibility. |
| Eden Radioisotopes | May-26 | Eden Radioisotopes submitted a construction permit application for a dedicated medical isotope production facility in New Mexico. The plant utilizes a specialized reactor concept optimized for high-yield isotope extraction, addressing domestic radiopharmaceutical supply constraints and bolstering infrastructure for targeted nuclear medicine therapies. |
| University of Missouri | Apr-25 | The University of Missouri signed a phase-one agreement to construct a new research reactor dedicated to expanding domestic nuclear medicine capabilities. The specialized facility is designed to scale up the production of essential medical isotopes for cancer treatments and reinforce national radiopharmaceutical research infrastructure. |
| NorthStar Medical Radioisotopes | Jan-23 | NorthStar Medical Radioisotopes successfully advanced its proprietary production technology to manufacture molybdenum-99 without relying on enriched uranium. This operational milestone enhances supply chain resilience for technetium-99m generators and establishes a more sustainable, non-proliferation-compliant manufacturing footprint in the nuclear medicine sector. |
| Novartis | Apr-23 | Novartis received U.S. FDA approval for its Milburn facility to commence commercial manufacturing of its targeted radioligand therapy, Pluvicto. The regulatory milestone significantly increases the company's automated production capacity to meet growing global demand for advanced prostate cancer treatments. |
| UCLA Health | Nov-25 | UCLA Health established a standalone Department of Nuclear Medicine and Theranostics to formalize its institutional focus on precision medicine. This organizational restructuring aims to integrate diagnostic imaging with targeted radiopharmaceutical therapies, accelerating clinical trials and optimizing operational workflows for oncology care. |
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
